JNJ vs PLX

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Protalix (PLX) continues to exhibit strong potential for 10x growth, building on its recent financial turnaround. The stellar Q1 2026 performance, with $18.3 million net income and $0.22 GAAP EPS (as noted in prior analysis and consistent with current P/E), substantially de-risks profitability concerns. The reaffirmed 2026 revenue guidance of $78–$83 million, backed by the $25 million Chiesi miles...